SCHEMBL4839593

SCHEMBL4839593

COc1c(Cl)cnc2[nH]c(-c3ccc(N)cc3)nc12

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 6/20 0.48
KMT2A Q03164 6/20 0.48
ALDH1A1 P00352 6/20 0.48
HPGD P15428 5/20 0.48
KDM4E B2RXH2 5/20 0.48
MAPT P10636 5/20 0.48
GAA P10253 4/20 0.48
HSD17B10 Q99714 4/20 0.48
GFER P55789 3/20 0.48
NPSR1 Q6W5P4 2/20 0.48
LMNA P02545 2/20 0.48
MITF O75030 1/20 0.48
BLM P54132 1/20 0.48
NPC1 O15118 6/20 0.45
SMN1; SMN2 Q16637 5/20 0.45
RAB9A P51151 5/20 0.45
TP53 P04637 4/20 0.45
GLA P06280 2/20 0.45
CYP1A2 P05177 1/20 0.45
CYP3A4 P08684 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4844297 0.81 JAK1 (0.44) IKBKETBK1JAK1JAK2JAK3
SCHEMBL4834739 0.81 JAK1 (0.49) PARP1IKBKETBK1JAK1JAK2
SCHEMBL4843765 0.81 TNKS (0.50) MEN1KMT2AALDH1A1HPGDMAPT
SCHEMBL4837291 0.74 BCL6 (0.46) MEN1KMT2AALDH1A1HPGDKDM4E
SCHEMBL4840913 0.74 ACHE (0.55) PARP1IKBKETBK1
SCHEMBL4838086 0.73 TBK1 (0.63) ALDH1A1KDM4ENPC1RAB9AIKBKE
SCHEMBL3084527 0.70 RHEB (0.56) KMT2AALDH1A1HPGDKDM4EMAPT
SCHEMBL3083372 0.69 RHEB (0.54) MEN1KMT2AALDH1A1HPGDKDM4E
SCHEMBL15756441 0.68 MAP4K4 (0.48) MEN1KMT2AALDH1A1HPGDKDM4E
SCHEMBL4846517 0.67 GAA (0.39) MEN1KMT2AALDH1A1HPGDKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7410966-B2 Use of and some novel imidazopyridines ASTRAZENECA AB (SE) 2008-08-12 US disclosed
EP-1539759-B1 NOVEL IMIDAZOPYRIDINES AND THEIR USE ASTRAZENECA AB (SE) 2007-08-15 EP disclosed
US-20050261333-A1 Use of and some novel imidazopyridines ASTRAZENECA A B (SE) 2005-11-24 US disclosed
EP-1539759-A1 USE OF AND SOME NOVEL IMIDAZOPYRIDINES AstraZeneca AB (SE) 2005-06-15 EP disclosed
WO-2004016611-A1 USE OF AND SOME NOVEL IMIDAZOPYRIDINES ASTRAZENECA AB (SE) 2004-02-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050261333-A1 Use of and some novel imidazopyridines ITK, CSNK1A1, RPS6KA1 MEN1 2592/4885KMT2A 2697/4885ALDH1A1 1489/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.